Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;88(3):438-452.
doi: 10.1002/ana.25808. Epub 2020 Jul 6.

Identifying Progression in Multiple Sclerosis: New Perspectives

Affiliations
Review

Identifying Progression in Multiple Sclerosis: New Perspectives

Massimo Filippi et al. Ann Neurol. 2020 Sep.

Abstract

The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden of progressive multiple sclerosis, and the recent development of effective treatments for these patients, there is a need to establish measures capable of identifying progressive multiple sclerosis early in the disease course. Starting from recent pathological findings, this review assesses the state of the art of potential measures able to predict progressive multiple sclerosis. Future promising biomarkers that might shed light on mechanisms of progression are also discussed. Finally, expansion of the concept of progressive multiple sclerosis, by including an assessment of cognition, patient-reported outcomes, and comorbidities, is considered. ANN NEUROL 2020;88:438-452.

PubMed Disclaimer

Comment in

  • Progressive Multiple Sclerosis.
    Khoury SJ. Khoury SJ. Ann Neurol. 2020 Sep;88(3):436-437. doi: 10.1002/ana.25802. Epub 2020 Jul 6. Ann Neurol. 2020. PMID: 32628321 No abstract available.

References

    1. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015;14:183-193.
    1. Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov 2019;18:905-922.
    1. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278-286.
    1. Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain 2015;138(pt 11:3287-3298.
    1. Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain 2016;139:2395-2405.

MeSH terms

LinkOut - more resources